Market Forces May Impact GDUFA III Talks
Executive Summary
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.
Topics
- Subjects
- Generic Drugs
- FDA
- Regulation
- Biosimilars
- Industries
- BioPharmaceutical
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB140198
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB140198
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.